Stoke Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
STOK Nasdaq 2836 www.stoketherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Oct 16th, 2026 2:20 pm
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Oct 12th, 2026 6:00 am
FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK) - Oct 9th, 2026 5:09 pm
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Oct 6th, 2026 6:00 am
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - Oct 5th, 2026 5:00 am
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization - Sep 23rd, 2026 2:01 pm
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Sep 3rd, 2026 5:30 pm
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Sep 2nd, 2026 6:00 am
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Sep 1st, 2026 5:30 am
Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating - Aug 21st, 2026 3:53 am
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts - Aug 17th, 2026 6:01 pm
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript - Aug 10th, 2026 7:58 pm
What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing? - Aug 7th, 2026 12:14 am
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Aug 5th, 2026 6:00 am
Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary - Aug 4th, 2026 6:30 am